SARS-CoV-2 Bivalent mRNA Vaccine

BIOLOGICAL2 trials

Sponsors

AIM Vaccine Co., Ltd.

Conditions

SARS-CoV-2

Phase 1

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

AIM Vaccine Co., Ltd.SARS-CoV-2

Start: 2023-08-10End: 2024-08-25Target: 60Updated: 2023-11-22

Phase 2

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

AIM Vaccine Co., Ltd.SARS-CoV-2

Start: 2023-10-09End: 2024-12-30Updated: 2023-11-24